Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

about

Optimal management of familial hypercholesterolemia: treatment and management strategies Inherited metabolic disorders and cerebral infarction.

P2860

Q34417480-98A63D01-8C23-4130-8E2E-0C1F7AD62C3D Q37318161-C01189C5-8A0C-4BB5-9AA9-D8A4680D131C

P2860

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

Item

http://www.wikidata.org/entity/Q36081978

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

@ast

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

@en

type

Item

label

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

@ast

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

@en

prefLabel

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

@ast

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

@en

P1476

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

@en

P2093

Nelva Mata

http://www.w3.org/2001/XMLSchema#string

Pedro Mata

http://www.w3.org/2001/XMLSchema#string

Rodrigo Alonso

http://www.w3.org/2001/XMLSchema#string

P2860

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Development of coronary heart disease in familial hypercholesterolemia

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group

Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

P304

171-181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.4.2.171

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15794711

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

about

P2860

P2860

Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921